

SUBJECT INDEX VOLUME 22

A

Abstinence, 581
Acoustic startle, 89
ACTH, 251
Addiction, 413
Adenosine A_{2A} receptors, 522
Adolescents, 440
Adrenocorticotropin, 595
Adults, 440
Age, 275
Aggression, 210, 320, 357
Alcohol, 581
Alcohol dependence, 493
Alcohol treatment, 493
Alcoholism, 133, 480, 493, 595
Amitriptyline, 380
Amphetamine, 14
Amygdala, 77
Animal model, 4, 400
Anpirtoline, 650
Antalarmin, 148
Anticonvulsants, 327
Antidepressant trials, 559
Antidepressants, 191, 327
Antidepressive & anxiolytic drugs, 422
Antimanic, 27
Antipsychotic medication, 19
Antipsychotics, 140, 642
Anxiety, 52, 77, 108, 230
Asperger's disorder, 163
Astressin, 230
Atrophy, 265
Attention, 200, 504
Auditory evoked potentials, 608
Autism, 163, 275
Autonomic nervous system, 388

B

Basolateral amygdala, 473
BDNF, 42
Bed nucleus of stria terminalis (BNST), 140
Behavior, 191, 357, 388, 618
Behavioral sensitization, 4, 551
Behavioral topography, 538
Benzodiazepines, 77
Bias, 559
Bulimia nervosa, 257
Bupirone, 440

C

Calcium, 36
Calcium channel blockers, 504
Calreticulin, 327
Carbamazepine, 530
[carbonyl-¹¹C]WAY-100635, 422
Cardiovascular activity, 52
Cardiovascular disease, 108
Caudate/putamen, 530
Central benzodiazepine receptor, 219
Cerebellar vermis, 466

Cerebral cortex, 36
Cerebrospinal fluid, 240
Cholecystokinin tetrapeptide (CCK-4), 251
Cholinergic, 200
Chronic caffeine treatment, 522
Circadian rhythm, 335
β-CIT, 133
Citalopram, 65, 513
Clock genes, 335
Clozapine, 140
Cocaine, 89, 413, 473, 551, 626
Cognition, 504
Cognitive testing, 14
Continuous Performance Test (CPT), 311
Corticosterone, 566
Corticotropin-releasing hormone, 148
Cortisol, 251
CP-226,269, 538
CP-293,019, 538
Craving, 626
CRF-antagonists, 230
CRH type 1 receptor, 388
Cytochrome-c oxidase, 284
Cytokines, 566

D

D2, 284
D2 dopamine receptors, 4
D2 occupancy, 19
D₄ agonists, 538
D₄ antagonists, 538
D₄ dopamine receptor, 538
2-Deoxyglucose, 545
Dependence, 581
Depression, 52, 108, 327, 335
Desipramine, 42
Development, 108, 440
DHPG, 320
Dopamine, 14, 52, 89, 125, 140, 168, 284, 545, 566, 618, 642
Dopamine D₁ and D₂ receptors, 522
Dopamine transporter, 133
Dopamine-beta-hydroxylase, 466
Dorsal hippocampus, 346
Dorsolateral prefrontal cortex, 125
Double blind, 311
DPheCRF₁₂₋₄₁, 148
Drug addiction, 626
Drug-naive, 97

E

Early experience, 219
Eating disorders, 257
Ecstasy, 513, 608
Electrophysiology, 642
Elevated plus-maze, 230
Emotionality, 65
Epinephrine, 320
Escalation, 413
Ethanol, 581
Ethological assessment, 538

Evoked release, 125
Extrapyramidal side effects, 311

F

Fear, 219
Flesinoxam, 650
Fluoxetine, 380
Forced swimming, 191
Fos, 530
Frontal lobe, 200

G

GABA_A receptor, 219
Gating, 89
Gene expression, 133
Gene transfer, 77
Genetics, 191
Geriatric depression, 265
Glucoprivation, 545
Glutamic acid decarboxylase-67, 430
Growth hormone, 163
GRP78, 327
GRP94, 327

H

Haloperidol, 311
Heroin, 413
Herpes virus vectors, 77
High intensity lesions, 265
Hippocampus, 65
Homeostasis, 108, 413
Hostility, 108
HPA system, 251
HPRT, 320
5-HT receptors, 168
5-HT_{1A} receptors, 346, 422
Human, 89, 504
5-hydroxyindoleacetic acid, 240
5-hydroxytryptamine, 148
Hypertension, 504
Hypothalamic-pituitary adrenal-axis, 388, 595

I

Ibotenic acid, 430
IBZM, 4
IL-1, 566
IL-6, 566
Imipramine, 346
Immune system, 370
Immunohistochemistry, 148
Impulsivity, 210
In situ hybridization, 27
Interleukin-6, 370
Isradipine, 504

K

Ketamine, 293, 400
Knock out mice, 451

L

L = 745,870, 538
Late-life depression, 265
Learning, 451
Lesch-Nyhan disease, 320
Limbic cortex, 400
Lithium, 346
Locomotor activity, 230, 430
Locus coeruleus, 27
LSD, 618

M

Macaca mulatta, 240
Magnetic resonance imaging, 265
Major depression, 265, 370
Manic state, 530
Maternal separation, 219
m-chlorophenylpiperazine (mCPP), 168
MDMA, 513, 608
Medical comorbidity, 265
Methamphetamine, 504, 530
3,4-methylenedioxymethamphetamine, 513, 608
Mice, 400
Microdialysis, 65, 140, 642
Mismatch negativity, 293
Mitochondria, 284
Monkey, 466
Monkey brain, 422
Monoamines, 566
Motor dysfunction, 19
Mouse, 97
Mousemutants, 380
Multiple drug resistance gene, 380

N

N-acetylaspartate, 125, 430
NAD-299, 422
Naloxone, 595
Naltrexone, 480, 493
Nefazodone, 493
Negative priming, 200
Negative symptoms, 14, 303
Neurochemical, 566
Neuroendocrine, 257
Neurotoxicity, 608
Nicotine, 200, 451
Nitric oxide synthase, 36
NMDA, 293, 618
NMDA antagonist, 400
Norepinephrine, 27, 52, 275, 566
Novelty, 219, 626
Nucleus accumbens, 473, 530

O

8-OH-DPAT, 168, 650
Opioid, 480, 595
Opioid peptides, 77
Org 4428, 42

P

P300, 293
Panic attacks, 251
Panic disorder, 251
Parkinson's disease, 522
Parkinsonism, 19
Paroxetine, 346
Paroxetine binding, 275
Passive avoidance, 168
p-chloroamphetamine (PCA), 168
PD 168077, 538
PET, 19, 545
P-Glycoprotein, 380
Phosphodiesterase type 4 inhibitor, 42
Positron emission, 422
Positron emission tomography, 19
Prefrontal cortex, 430, 642
Prepulse inhibition, 89, 551
Primate, 4, 210
Processing negativity, 293
Psychological effects, 513
Psychomotor responses, 480
Psychomotor stimulants, 4
PTSD, 108
Purkinje cells, 466
Putamen, 284

R

Raclopride, 545
Randomized control trial, 493
Rat, 36
Rat₁, 581
Receptor, 284
Reinforcement, 451
Reinstatement, 626
Relapse, 413, 473, 581
REM sleep, 440
Repetitive behavior, 163
Reward, 473
r/hCRF, 230
Risperidone, 311
Ro 20-1724, 42
Ro 61-6270, 538
Robalzotan, 422
Rolipram, 42
RU 24969, 650

S

Schizophrenia, 125, 284, 293, 303, 400, 466, 551, 618, 642
Schizophrenia spectrum, 14
Scopolamine, 97
Seasonal affective disorder, 335

Seasonal variation, 240
Selective attention, 293
Selective serotonin reuptake inhibitors, 513
Self-administration, 97, 413, 473, 581, 626
Self-injurious behaviour, 320
Sensitization, 626
Sensorimotor gating, 551, 650
Serotonergic, 440
Serotonin, 52, 163, 210, 257, 275, 357, 513, 566, 608, 618
Serotonin reuptake, 65
Serotonin transporter, 275
Set-point, 413
SLC6A3, 133
Sleep, 210
Social stress, 230
Socioeconomic status, 108
SPECT, 133
Startle habituation, 650
Stereotyped behavior, 4
Strain differences, 191
Stress, 52, 108, 148, 413, 626
Striatum, 4, 125, 430, 545
Study validity, 559
Subjective responses, 480
Substance abuse, 108
Suicide, 327
Sumatriptan, 163
Synaptosomes, 36, 65
Synergism, 566

T

Therapy resistance, 380
TNF- α , 566
Tomography, 422
Tranylcypromine, 346
Treatment, 303
Treatment response, 370
Triiodothyronine, 36
Tryptophan, 52, 275, 357
Tryptophan depletion, 357
Tumor-necrosis factor- α , 370
Tyrosine, 275
Tyrosine hydroxylase, 27

U

Unblinded rater, 559

V

Valproic acid, 27
Visuospatial working memory, 14
Vulnerability indicator, 311

W

WAY 100635, 346
Working memory, 200

Y

Yoked control, 97